Fortum Dosage/Direction for Use

Dosage depends upon the severity, sensitivity, site and type of infection and upon the age and renal function of the patient.
Use Ceftazidime (Fortum) injection by intravenous (i.v.) or deep intramuscular (i.m.) injection. Recommended i.m. injection sites are the upper outer quadrant of the gluteus maximus or lateral part of the thigh.
Ceftazidime (Fortum) solutions may be given directly into the vein or introduced into the tubing of a giving set if the patient is receiving parenteral fluids.
Adults: 1 to 6 g/day in two or three divided doses by i.v. or i.m. injection.
Urinary tract and less severe infections: 500 mg or 1 g every 12 hours.
Most infections: 1 g every 8 hours or 2 g every 12 hours.
Very severe infections particularly in immunocompromised patients including those with neutropenia: 2 g every 8 or 12 hours, or 3 g every 12 hours.
Fibrocystic adults with pseudomonal lung infections: 100 to 150 mg/kg/day in three divided doses.
In adults with normal renal function 9 g/day has been used without ill effect.
When used as a prophylactic agent in prostatic surgery, 1 g should be given at the induction of anaesthesia. A second dose should be considered at the time of catheter removal.
Infants and children (greater than 2 months): 30 to 100 mg/kg/day in two or three divided doses.
Doses up to 150 mg/kg/day (maximum 6 g/day) in three divided doses may be given to infected immunocompromised or fibrocystic children or children with meningitis.
Neonates (0 to 2 months): 25 to 60 mg/kg/day in two divided doses.
In neonates, the serum half-life of ceftazidime can be three to four times that in adults.
Elderly: In view of the reduced clearance of ceftazidime in acutely ill elderly patients, the daily dosage should not normally exceed 3 g, especially in those over 80 years of age.
Renal Impairment: Ceftazidime is excreted unchanged by the kidneys. Therefore, in patients with impaired renal function, the dosage should be reduced. An initial loading dose of 1 g should be given. Maintenance doses should be based on creatinine clearance as shown in Table 2: See Table 2.

Click on icon to see table/diagram/image

In patients with severe infections the unit dose should be increased by 50% or the dosing frequency increased. In such patients the ceftazidime serum level should be monitored and trough levels should not exceed 40 mg/L.
In children the creatinine clearance should be adjusted for body surface area or lean body mass.
Haemodialysis: The serum half-life during haemodialysis ranges from 3 to 5 hours.
Following each haemodialysis period, the maintenance dose of Ceftazidime (Fortum) recommended in the previous table should be repeated.
Peritoneal dialysis: Ceftazidime (Fortum) may be used in peritoneal dialysis and continuous ambulatory peritoneal dialysis (CAPD).
In addition to i.v. use, Ceftazidime (Fortum) can be incorporated into the dialysis fluid (usually 125 to 250 mg for 2 litres of dialysis solution).
For patients in renal failure on continuous arteriovenous haemodialysis or high-flux haemofiltration in intensive therapy units; 1 g daily either as a single dose or in divided doses. For low-flux haemofiltration, follow the dosage recommended under impaired renal function.
For patients on venovenous haemofiltration and venovenous haemodialysis, follow the dosage recommendations in Tables 3 and 4 as follows. (See Tables 3 and 4.)

Click on icon to see table/diagram/image


Click on icon to see table/diagram/image